Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Early Stage|Triple Negative Breast Cancer
Interventions: DRUG: Enzalutamide|BEHAVIORAL: assessment
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Medivation, Inc.|Astellas Pharma Inc